Enterprise Value
352.3M
Cash
42.93M
Avg Qtr Burn
-5.846M
Short % of Float
7.12%
Insider Ownership
2.47%
Institutional Own.
26.27%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Auryxia (ferric citrate) Details Chronic kidney disease, Anemia, Kidney disease, Hyperphosphatemia | Approved Update | |
Vafseo™ (Vadadustat) Details Chronic kidney disease, Anemia, Kidney disease | Approved Quarterly sales |